Clinical Trials Logo

Filter by:
NCT ID: NCT05006560 Recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

Internet-based Rehabilitation Aftercare Focusing on Physical Activity Promotion in Persons With COPD

COPD-AReNa
Start date: July 5, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate a 12-week internet-based rehabilitation aftercare program with an emphasis on physical activity promotion for persons with COPD. The program starts directly after an inpatient pulmonary rehabilitation program. It includes monitoring and promotion of physical activity, progressive resistance and endurance training, education through online learning modules and continuous support from a therapist.

NCT ID: NCT05005949 Recruiting - Clinical trials for Persistent Atrial Fibrillation

STOP Persistent AF PAS

Start date: August 19, 2021
Phase:
Study type: Observational

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

NCT ID: NCT05005676 Recruiting - Neuromuscular Block Clinical Trials

Evaluation of the New Acceleromyograph TOF 3D

Start date: August 31, 2021
Phase: N/A
Study type: Interventional

The TOF 3D is a new acceleromyograph designed to assess the degree of a neuromuscular block during anesthesia. The study compares the new three-dimensional technique with the established TOF Watch SX.

NCT ID: NCT05003986 Recruiting - Clinical trials for Focal Segmental Glomerulosclerosis

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

EPPIK
Start date: August 12, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

NCT ID: NCT05002543 Recruiting - Clinical trials for Cardiac Valve Disease

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

MANTRA
Start date: June 29, 2021
Phase:
Study type: Observational [Patient Registry]

MANTRA is a prospective, multiple-arm, multi-center, global, post-market clinical follow-up study. The main objective is to monitor ongoing safety and performance of the CORCYM devices and accessories used for aortic, mitral and tricuspid valvular diseases in a real-world setting. Corcym S.r.l., is a medical device manufacturer with a broad product portfolio for cardiac surgeons, offering solutions for the treatment of aortic, mitral and tricuspid valve disease. The MANTRA Master Plan (Master Protocol) is intended as an overarching Umbrella Protocol that allows multiple sub-studies to be added, as needed. The Umbrella Master Protocol concept offers an excellent solution to provide post-marketing clinical follow-up information on the entire cardiac surgery heart valve portfolio of the sponsor in a common database, including corelab assessment of hemodynamic and structural performance, annular motion and Dynamics for one of the products. Currently, three sub-studies are planned: - MANTRA - Aortic Sub-Study - MANTRA - Mitral/Tricuspid Sub-Study (Excluding Memo 4D) - MANTRA - Memo 4D Sub-Study

NCT ID: NCT05002023 Recruiting - Pregnancy Clinical Trials

PRINCE Study - Cohort Study of Healthy Pregnant Women Followed by the Assessment of Children´s Health and Immunity

PRINCE
Start date: February 2, 2011
Phase:
Study type: Observational

In the PRINCE study we recruit healthy but also diseased pregnant women into a cohort study, followed by the assessment of children´s health and immunity at birth and during the first 10 years of life. This unique cohort allows for testing the impact of prenatal challenges on children´s health.

NCT ID: NCT05001737 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

EMERALD
Start date: December 15, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.

NCT ID: NCT05001269 Recruiting - Clinical trials for Primary Hyperoxaluria

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

PHYOX8
Start date: February 22, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.

NCT ID: NCT05000255 Recruiting - Covid19 Clinical Trials

Coping With Covid-19: Loneliness, Self-Efficacy, Social Support, Depression & Anxiety in Patients in Medical Rehab.

Start date: January 18, 2021
Phase: N/A
Study type: Interventional

Aim of the study is to investigate possible predictors and factors that may be associated with the development and maintenance of mental and physical health constrains including depression and anxiety symptomatology as well as loneliness in hospitalized post-COVID patients and non-COVID patients in Germany. Furthermore, it will be investigated whether psychological interventions have an effect on anxiety and depression symptomatology, on loneliness values, self-efficacy and perceived social support values. Specifically, the research aim is to examine the relationships between loneliness, self-efficacy, and social support and to address the question of what factors increase the risk of post covid depression/anxiety, and to test the buffering effect of physical and social activities. For this purpose an experimental group comparison will be applied, in which two interventions will be performed on post-COVID patients and non-COVID patients in the unit of Physical Medicine and Geriatrics in Medical Rehabilitation. (PhD Project by Annika Roskoschinski, M.Sc., Psychology, Principal Investigator)

NCT ID: NCT04996875 Recruiting - Clinical trials for Aggressive Systemic Mastocytosis (ASM)

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Start date: November 9, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).